Detail akcie OncoArendi Br online

Business Summary: Molecure SA, formerly known as Oncoarendi Therapeutics SA, is a Poland-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Company's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The Company has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Molecure SA revenues increased from PLN636K to PLN3.6M. Net loss decreased 33% to PLN14M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects External Expense decrease of 35% to PLN3.5M (expense), Depreciation & Amortization decrease of 19% to PLN2.3M (expense).